24
73. V.Kanti, A. Messenger, G. Dobos, P. Reygagne, A. Finner, A. Blumeyer, M. Trakatelli, A. Tosti,
V. del Marmol, B.M. Piraccini, A. Nast, U. Blume-Peytavi. Evidence-based (S3) guideline for the
treatment of androgenetic alopecia in women and in men – short version. JEADV 2018, 32, 11–22
74. V. Kanti, K. Hillmann, J. Kottner, A. Stroux, D. Canfield, U. Blume-Peytavi Effect of minoxidil
topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104- week open-label
clinical trial. JEADV 2015, р.1-7
75. Pazoki-Toroudi H, Babakoohi S, Nilforoushzadeh MA et al. Therapeutic effects of minoxidil high
extra combination therapy in patients with androgenetic alopecia. SKINmed 2012; 10: 276– 282
76. DeVillez RL, Jacobs JP, Szpunar CA et al. Androgenetic alopecia in the female. Treatment with
2% topical minoxidil solution. Arch Dermatol 1994; 130: 303– 307
77. Lucky AW, Piacquadio DJ, Ditre CM et al. A randomized, placebo-controlled trial of 5% and 2%
topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad
Dermatol 2004; 50: 541– 553
78. Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, Trakatelli M, Tosti A, Del
Marmol V, Piraccini BM, Nast A, Blume-Peytavi U. Evidence-based (S3) guideline for the
treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol
Venereol. 2018 Jan;32(1):11-22. doi: 10.1111/jdv.14624. Epub 2017 Nov 27. PMID: 29178529
79. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review
and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136-141.e5. doi:
10.1016/j.jaad.2017.02.054. Epub 2017 Apr 7. PMID: 28396101
80. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the
treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.
Journal of the American Academy of Dermatology. 1998;39(4 Pt 1):578-89
81. Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count
in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. Journal of the
American Academy of Dermatology. 2002;46(4):517-23
82. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic
alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. Journal of the
American Academy of Dermatology. 2006;55(1):71- 4
83. Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, et al. Efficacy and tolerability of
finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. European journal of
dermatology EJD. 2003;13(2):150-60
84. Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with
androgenetic alopecia. Journal of Dermatology. 2012;39(1):27- 32
85. Rossi A, Cantisani C, Scarno M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily
administration on male androgenetic alopecia in different age groups: 10-year follow-up.
Dermatologic Therapy. 2011;24(4):455-61
86. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual
5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized
placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of
Dermatology. 2006;55(6):1014-23
87. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins.
Journal of cosmetic dermatology. 2007;6(1):9-13
88. Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, et al. Effect of dutasteride 0.5 mg/d in
men with androgenetic alopecia recalcitrant to finasteride. International Journal of Dermatology.
2014;53(11):1351-7
89. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of
dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-
blind, placebo-controlled, phase III study. Journal of the American Academy of Dermatology.
2010;63(2):252-8